BPT Crunch

Companies on the Cutting Edge of Healthcare Innovations

back to Marketplace

Akcea Therapeutics

Akcea Therapeutics logo

Founded
2014
Clinical Trials
13
Publications
27

Technologies

Antisense Oligonucleotides

Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals, Inc., is a development and commercialization company focused on transforming serious cardiometabolic lipid disorders. Akcea&s;s portfolio spans multiple targets and disease states, including both rare and more common lipid disorders, using advanced RNA-targeted antisense therapeutics.


Posts Mentioning This Company

Antisense Oligonucleotides Make Sense

  
Antisense oligonucleotides (ASOs) are short (about 12 to 25 nucleotides long), synthetic single strands of DNA or RNA that are complementary to a chosen sequence. They can alter RNA and reduce, restore, or modify protein expression. ASOs interact with proteins on the surface of cells and enter the cytoplasm. Then …
SHARE